Literature DB >> 34295599

Management Strategies for Dealing With Surges of the COVID-19 Pandemic.

A V Raveendran1,2, Jothydev Kesavadev3, Parameswaran Hari4, Gopika Krishnan3.   

Abstract

The spread of COVID-19 (coronavirus disease 2019) across the world has resulted in widespread morbidity and mortality. An explosive increase in the number of cases during the surge phase of the pandemic can result in a management crisis. Therefore, we propose a simple model to manage the surges of the pandemic.
Copyright © 2021, Raveendran et al.

Entities:  

Keywords:  covid-19; home treatment; management; pandemic; sars-cov-2

Year:  2021        PMID: 34295599      PMCID: PMC8293859          DOI: 10.7759/cureus.15794

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, which started in Wuhan, China has by now spread all over the world causing widespread morbidity and mortality. An explosive increase in the number of cases occurs during the surges of the pandemic when even developed countries fail to accommodate and manage it properly. In addition to the shortage of hospital beds, ICU beds, ventilators, oxygen, and essential drugs, even the number of health care providers becomes insufficient to provide care in most situations of explosive spread. During the peak of the pandemic, similar crises have been reported from all parts of the world. To tide over the crisis, health care workers are forced to work continuously and still fail to address the issues. Proper planning and anticipation can help to utilize the resources more efficiently thereby enabling the provision of appropriate care to a larger number of citizens.

Technical report

As of 17 May 2021, the total number of cases of COVID-19 (coronavirus disease 2019) in India is around 25,227,970 and around 3,50,000 new cases are being added to this daily during the peak of the ongoing second wave [1]. Patients with a severe disease along with hypoxia require ventilators for an average of three to six days which can even be extended for weeks and to top this, new critical cases are also added every day resulting in a severe shortage of ventilators, oxygen supply, essential medicines, and hospital beds. However, only about 1.9 million hospital beds, 95,000 ICU beds, and 48,000 ventilators are available in India to fight against this crisis [2]. We propose a simple model to manage a pandemic surge, as even a well-established health system may fail to accommodate a large number of cases (Figure 1 and Table 1).
Figure 1

Proposed model to manage the surges of the pandemic

Table 1

Monitoring and treatment options of COVID-19 at different levels

H2 blocker: Histamine-2 receptor blocker; PPI: Proton pump inhibitor; COVID-19: Coronavirus disease 2019.

SymptomsMonitoringTreatment
At-home quarantine
FeverTemperatureParacetamol
Body acheAnti-histamines
HeadachePulse rateAntibiotics
Running noseCough syrup
CoughRespiratory rateH2 blockers/PPI
Throat painSteroids
BreathlessnessBlood pressureAnti-coagulants
Abdominal discomfort
DiarrheaOxygen saturation (SpO2)
Any co-morbiditiesBlood glucose with glucometerOptimization of treatment of co-morbidities
Full blood count, inflammatory markers, and biochemical panels if healthcare workers visit
At first line facility/ field hospital  
BreathlessnessAll of the aboveAll of the above
Chest X-rayInj. Dexamethasone
Routine blood test including inflammatory markers  and biochemical panelsMonoclonal antibody- Inj. Tocilizumab
Inj. Heparin
Oxygen
Deterioration of comorbid conditionMonitoring of comorbiditiesOptimization of treatment of comorbidities
At multidisciplinary tertiary level care  
Breathlessness even at maximal oxygen supplementationAll of the aboveAll of the above
Investigations as per patients profileVentilator support
Deterioration of comorbid conditionMonitoring of comorbiditiesOptimization of treatment of comorbidities
Early identification of complicationsMonitoring of complicationsTreatment of complications

Monitoring and treatment options of COVID-19 at different levels

H2 blocker: Histamine-2 receptor blocker; PPI: Proton pump inhibitor; COVID-19Coronavirus disease 2019.

Discussion

The majority of people affected with COVID-19 develop only asymptomatic or mildly symptomatic disease [3, 4]. Those who develop mild COVID-19 should be monitored and treated at home by trained family members or volunteers, with intermittent support from healthcare providers. The latter may recommend simple treatment measures like paracetamol, antihistamines, cough syrup, etc (Figure 2) [5]. Managing asymptomatic and uncomplicated cases (which constitute the majority of the cases during this pandemic) at home is the key step in the success of the management strategy.
Figure 2

Treatment options during home quarentine

Those who have significant symptoms or associated co-morbidities should be monitored more closely by trained paramedical staff under the supervision of a doctor. The latter may administer drugs like antibiotics, anticoagulants, steroids, etc., depending upon the clinical scenario. Finally, those with moderate-to-severe COVID-19 or deteriorating symptoms such as hypoxia requiring oxygen should be shifted to hospitals, where volunteers, paramedical staff, and doctors are at hand to take care of these patients. Those developing hypoxia despite oxygen support may require positive-pressure ventilation support or multi-disciplinary interventions. Therefore, they should be shifted to tertiary-care facilities. We propose that this strategy will reduce unnecessary hospital admissions and resource utilization, thereby helping appropriate allocation of scarce resources to needy patients.

Conclusions

The adoption of the approach suggested by us will allow effective management of the pandemic, reduce unnecessary hospital admissions and expenditure, enable triaging of cases, and allow optimal engagement of healthcare professionals, thereby reducing the mortality and morbidity associated with the pandemic.
  2 in total

1.  Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19.

Authors:  G-U Kim; M-J Kim; S H Ra; J Lee; S Bae; J Jung; S-H Kim
Journal:  Clin Microbiol Infect       Date:  2020-05-01       Impact factor: 8.067

2.  Out-of-Hospital Cohort Treatment of Coronavirus Disease 2019 Patients with Mild Symptoms in Korea: an Experience from a Single Community Treatment Center.

Authors:  Peong Gang Park; Chang Hyup Kim; Yoon Heo; Tae Suk Kim; Chan Woo Park; Choong Hyo Kim
Journal:  J Korean Med Sci       Date:  2020-04-06       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.